GSK3882347

Unknown / undisclosed

Automated registry profile: compiled from public clinical-trial and regulatory records; not yet individually analyst-verified.

Earlyevidence

Evidence outlook

Early-stage evidence only

Phase 1 / first-in-human studies establish safety, tolerability, and dosing; they are not designed to demonstrate efficacy, so no evidence signal is assigned yet. The first graded signal arrives with a completed confirmatory readout.

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 1 (3)
Urinary Tract Infection
NCT05138822 · GlaxoSmithKline
2022-05-18 – 2024-12-03 · Uncomplicated Urinary Tract Infections, Urinary Tract Infections
What this study did
NCT05760261 · GlaxoSmithKline
2023-04-11 – 2024-08-20 · Urinary Tract Infections
What this study did
NCT04488770 · GlaxoSmithKline
2020-08-24 – 2021-05-14 · Urinary Tract Infections
What this study did

Competitive landscape

This drug's own stage for Urinary Tract Infection: Phase 1. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
GSK3882347: this drugPhase 1UndisclosedFimHnot yet gradedNo reviewed efficacy summary in this indication
GSK5102188
—(overall)
Vaccine—not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

No upcoming readouts on record for this asset.